Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The global pet cancer therapeutics market, by therapy (Chemotherapy, Targeted Therapy, Combination Therapy, and Immunotherapy), by pet type (Cat, Dog, and Horse), by mode of administration (Oral, Intravenous, and Topical), by application (Lymphoma, Mast Cell Cancer, Melanoma, Mammary and Squamous Cell Cancer, and Others) and by region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa), was evaluated at US$ 183.3 million in 2017 and now expected to exhibit a CAGR of 7.7% over the forecast period (2017-2025).
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/1284
Rising global awareness about the importance of early diagnosis of pet cancers, adoption of novel therapies with acclaimed safety profiles, growing veterinary healthcare expenditure, multiple drugs currently in the pipeline, and increasing R&D initiatives are significant aspects that offer a major impetus to the global pet cancer therapeutics market growth.
Several globally recognized veterinary pharmaceutical companies have been focusing on strategic collaborations to develop and commercialize certain cancer treatments for companion animals. For instance, Karyopharm and Anivive Lifesciences entered into an exclusive license agreement in 2017, for the research, development, and commercialization of Verdinexor (KPT-335) – a drug intended for the treatment of lymphoma. The U.S. FDA Center for Veterinary Medicine (CVM) has found effectiveness and safety technical sections for Verdinexor to support the conditional approval under a New Animal Drug Application (NADA) for the treatment of canine lymphoma. The drug candidate was further granted the Minor Use & Minor Species (MUMS) designation.
Special Requirements?
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/1284
The key companies operating in the global pet cancer therapeutics market include Aratana Therapeutics, Inc., AB Science, Boehinger Ingelheim International GmbH, Zoetis, Zenoaq, Morphogenesis, Inc., VetDC, Inc., Karyopharm Therapeutics, Inc., Regeneus Ltd., Rhizen Pharmaceuticals SA, and Oasmia Pharmaceuticals AB.
These market contenders are actively engaged in the development, licensing, and commercialization of effective pet therapeutics. For instance, in 2017, Doxosphos Vet, a patented formulation of doxorubicin and the XR17 technology by Oasmia Pharmaceuticals AB, was developed for the treatment of lymphoma in dogs. The drug candidate was subsequently granted the MUMS designation by the U.S. FDA. Furthermore, in 2015, Rhizen Pharmaceuticals S.A. initiated the Phase 2 study of RV1001, a novel oral selective inhibitor of PI3K delta, which is indicated for the treatment of lymphoma in dogs. Moreover, increasing investments by pet owners in disease treatments propel the growth of the global market. As per an annual survey carried out by the American Pet Products Association in 2015, most people in the U.S. spend an estimated US $15.4 billion on veterinary care each year.
Browse Press Release: https://bit.ly/3cZHQJL
Key Market Takeaways:
- Among therapy types, the chemotherapy segment holds the foremost position in the global pet cancer therapeutics market, primarily owing to the easy availability of chemotherapy drugs.
- Among pet types, the dogs segment dominates the global market, owing to the higher prevalence of cancer among dogs, as compared to the other pets.
- In terms of application, the lymphoma segment leads the global pet cancer therapeutics market, with the largest number of lymphoma cases among pet animals and a huge number of therapeutics approved for this treatment.
- Increasing incidence of pet cancers, and high pet adoption rates in Europe, Asia Pacific, and Latin America act as pivotal market growth boosters.
Apply Promo Code “STAYHOME” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1284
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
